Ran Zioni
Mergers & Acquisitions
- Future Electronics, a global electronics distribution company, in its announced $3.8 billion sale to Taiwan-based WT Microelectronics (TAIEX: 3036)
- Biolog-id, a digital health solution provider focusing on value-chain optimization, in its proposed business combination valuing Biolog-id at $312 million, with the SPAC, Genesis Growth Tech Acquisition Corp. (Nasdaq: GGAA)
- Hyperfine, Inc. (Nasdaq: HYPR) business combination, valued at $580 million, with Liminal Sciences and the SPAC, HealthCor Catalio Acquisition Corp.
- The Metals Company’s (Nasdaq: TMC), formerly DeepGreen Metals, $2.9 billion business combination with the SPAC, Sustainable Opportunities Acquisition Corporation
- Optum’s proposed acquisition of Atrius Health
- Quantum-SI’s (Nasdaq: QSI) business combination, valued at $1.46 billion, with the SPAC, HighCape Capital Acquisition Corp.
- Butterfly Network’s (NYSE: BFLY) $1.5 billion business combination with the SPAC, Longview Acquisition Corp.
- QIAGEN in its proposed $12.5 billion sale to Thermo Fisher Scientific
- Represented Dassault Systèmes in its $425 million acquisition of IQMS, Inc.
- Brooks Automation’s approximately $450 million purchase of genomics service provider Genewiz Group
- John Hancock Financial Network’s sale of Signator Investors to Advisor Group
- Connance’s sale to Waystar Health
- Optum’s purchase of Reliant Medical Group
- Princeton Lightwave's sale to Argo AI, a subsidiary of Ford Motor Company
- John Hancock Financial Network’s purchase of Symetra Investment Services
- C&S Wholesale Grocers’ purchase of the assets of Associated Wholesalers
- C&S Wholesale Grocers’ purchase of the assets of Davidson Co., Inc.
- John Hancock Financial Network’s purchase of the assets of Transamerica Financial Advisors
- Naurex’s sale to Allergan
- Leerink Swann’s sale of the assets of Leerink Swann Consulting to NCI Healthcare
- Humedica's sale to UnitedHealth Group
- Piramal Healthcare Limited's $635 million purchase of Decision Resources Group
- iMDsoft’s $60 million sale to TPG
- Merger of Arbinet Corporation with Primus Telecommunications
- Management buyout of private equity-backed printing company
- Sale of software company to large strategic buyer
Licensing and Outsourcing
- Representing leading robotic systems developers for automated fulfillment in retail, eCommerce, and logistics industries in complex, multi-year sales, deployment and maintenance relationships
- Represented a Health IT software provider in licensing a core platform to a Fortune 20 customer to support a new line of business
- Represented client in a software platform integration agreement with a worldwide leading software and services integrator
- Represented large fund company in enterprise-wide fund administration outsourcing agreement with a leading provider
- Represented large financial institution in the outsourcing of a critical, regulatory business function to an industry-leading service provider
- Represented large financial institution in the simultaneous outsourcing of two core regulated business functions to an industry-leading service provider

Mintz is advising DeepGreen Metals Inc., a company developing a new source of electric vehicle battery metals from polymetallic nodules found on the seafloor, in its proposed merger with Sustainable Opportunities Acquisition Corporation, a special purpose acquisition company (SPAC) focused on ESG.

Mintz is acting as legal advisor to Quantum-SI Incorporated, developer of a pioneering semiconductor chip to sequence proteins, in its proposed business combination with HighCape Capital Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by growth equity investment firm HighCape Capital LP.

Mintz served as legal advisor to Butterfly Network Inc., an innovative digital health company, in its merger with Longview Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by Glenview Capital Management, LLC.

Mintz attorneys negotiated a termination agreement with a large Indian technology vendor that had failed to meet the terms of its contract. The successful negotiation eased the client's transition to a new vendor while preserving the client's right to enforce claims against the old provider.

Mintz represented clinical-stage biopharmaceutical company Naurex Inc., which develops therapies for central nervous system disorders, in its acquisition by global pharmaceutical company Allergan PLC for $560 million plus potential milestone payments. Naurex’s platform was spun out into a new company.